| __timestamp | Opthea Limited | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 2917513 |
| Thursday, January 1, 2015 | 2361587 | 7878291 |
| Friday, January 1, 2016 | 4472869 | 8366794 |
| Sunday, January 1, 2017 | 5030957 | 6610381 |
| Monday, January 1, 2018 | 4988941 | 6556000 |
| Tuesday, January 1, 2019 | 5196412 | 6930000 |
| Wednesday, January 1, 2020 | 6652774 | 8758000 |
| Friday, January 1, 2021 | 18418247 | 10806000 |
| Saturday, January 1, 2022 | 24827066 | 9844000 |
| Sunday, January 1, 2023 | 41896408 | 13481000 |
| Monday, January 1, 2024 | 15488619 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Opthea Limited and Soleno Therapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Opthea's SG&A expenses surged by over 1,400%, peaking in 2023. This dramatic increase suggests aggressive expansion or investment in administrative capabilities. In contrast, Soleno's expenses grew by approximately 360% during the same period, indicating a more conservative approach.
Interestingly, in 2021, Opthea's expenses were nearly 70% higher than Soleno's, highlighting a significant divergence in cost management strategies. However, the data for 2024 is incomplete, leaving room for speculation on future trends. As investors and analysts look to the future, understanding these cost dynamics will be key to evaluating each company's strategic direction.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Soleno Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Opthea Limited
Opthea Limited or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Opthea Limited vs MorphoSys AG Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Opthea Limited vs Geron Corporation
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Soleno Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?